Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
HCV incidence in a Canadian study was lower than rates seen in some European countries.
A pair of studies found that bacteriophage therapy may treat alcoholic hepatitis and primary sclerosing cholangitis.
In a Phase II study, the drug was safe and well tolerated, and a small number of people achieved benchmarks of success against the virus.
People treated with Viread, Vemlidy or Baraclude are less likely to develop this malignancy.
Opdivo plus Yervoy led to higher response rates and longer survival than Opdivo alone.
Adults with chronic liver disease are more than twice as likely than those without the condition to have barriers to medical care.
Nevertheless, researchers are hoping to learn more from the study of the caspase inhibitor among people with non-alcoholic steatohepatitis.
A new classification system may more accurately reflect liver-related death trends in the United States.
Drugs that have a favorable effect on biomarkers may still play a role in combination therapy, however.
Some study participants experienced hepatitis B surface antigen loss, considered a functional cure.
This is the first major study to assess an eight-week regimen in people with all genotypes of hep C and compensated cirrhosis.
A new study shows that people with the liver disease have substantial financial burden that can impact their care.
A large Canadian study found that just 2% of such women developed more severe cirrhosis within one year of delivery.
The tool relies on 14 clinical variables, such as liver enzymes, body mass index, triglycerides, height and sex.
This rapid regimen could open the door for more transplantations of HCV-infected organs.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.